

Interim report for the period 1 January – 30 June 2015

Announcement No. 7/2015

To NASDAQ Copenhagen

Exiqon A/S  
 Skelstedet 16  
 2950 Vedbæk  
 Denmark

Phone: +45 4566 0888  
 Fax: +45 4566 1888  
 exiqon@exiqon.com  
 www.exiqon.com

25 August 2015

## Continued strong performance in the second quarter with 24% growth and profitability

Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced results for the second quarter and first six months of 2015:

Financial Highlights (DKK million)	Q2 2015	Q2 2014	Q2 change	H1 2015	H1 2014	H1 change
Revenue	38.0	30.7	24%	77.0	63.2	22%
Gross profit	24.8	20.2	23%	50.8	42.3	20%
EBITDA	2.6	0.1	4019%	5.2	1.7	206%
EBIT	0.8	-1.5	N/A	1.8	-1.1	N/A
Net profit	0.0	-1.2	N/A	0.0	-0.5	N/A
Cash flows from operating activities	3.4	1.3	156%	4.7	-1.0	N/A

Summarized financial numbers are compared to full year outlook on p.3.

### Revenue highlights

- Exiqon successfully continues to execute its growth strategy towards becoming the leading provider of flexible solutions for RNA analysis by leveraging existing capabilities and capture new markets. RNA services and product sales (excluding OEM) are the key drivers for Exiqon’s growth. In the second quarter sales increased 24% to DKK 30.7 million (DKK 24.9 million):
  - Services offer the highest short-term potential for growth besides paving the way for development of new proprietary products and so initially drive Exiqon’s growth. In the second quarter services increased 59% to DKK 5.9 million (DKK 3.7 million).
  - Product sales offer high potential for growth in the mid-term growth as Exiqon increasingly targets new sizable markets for RNA sequencing and RNA functional analysis. In the second quarter sales increased 17% to DKK 24.8 million (DKK 21.1 million).
- Other income include license income and grant funding of Exiqon’s development of novel diagnostics within prostate and colorectal cancer that hold promise of transforming current healthcare practices and improve patient care. In the second quarter of 2015 other income decreased 13% to DKK 3.1 million (DKK 3.5 million).

### Operational highlights

- In the second quarter Exiqon continued to expand its product offering and target new market opportunities: On 26 May, 2015 Exiqon launched new Antisense LNA™ GapmeRs for RNA functional analysis and on 30 June, 2015 Exiqon launched a new qPCR portfolio for real-time PCR analysis of mRNAs and long non-codingRNAs.
- On 30 June, 2015 Exiqon launched its innovative XploreRNA™ cloud-computing environment, leveraging existing bioinformatics capabilities, and bringing together for the first time applications for RNAseq data analysis with custom assay design in one integrated work-flow supported by a full-fledged e-commerce system.

In a comment CEO Lars Kongsbak said: *“Another great quarter for Exiqon. We continue to deliver high growth, increased innovation and profitability. We are excited about our new cloud initiative that propels Exiqon to the forefront of providers of flexible solutions for RNA analysis.”*

Exiqon raises its full year guidance to revenues of DKK 155-160 million (previously DKK 150-160 million) and EBITDA around DKK 10 million (previously DKK 5-10 million) based on an average USD/DKK exchange rate of DKK 6.50.

## KEY FIGURES AND RATIOS – EXIQON GROUP (UNAUDITED)

(DKK'000 except key figures and ratios)	1 Apr. – 30 Jun. 2015	1 Apr. – 30 Jun. 2014	1 Jan. – 30 Jun. 2015	1 Jan. – 30 Jun. 2014	1 Jan. – 31 Dec. 2014
<b>Income statement</b>					
Revenue	38,016	30,722	77,038	63,193	132,392
Production costs	-13,176	-10,505	-26,270	-20,930	-47,193
Gross profit	24,840	20,217	50,768	42,263	85,199
Research and development costs	-7,733	-6,469	-16,052	-13,138	-26,283
Sales and marketing costs	-11,951	-10,510	-24,131	-20,901	-43,087
Administrative costs	-4,334	-4,765	-8,814	-9,280	-18,911
EBITDA *)	2,554	62	5,235	1,708	3,107
Operating profit/(loss) (EBIT)	822	-1,527	1,771	-1,056	-3,082
Profit/(loss) for the period	15	-1,243	44	-450	-2,780
Total Comprehensive profit/(loss) for the period	-669	-1,153	536	-404	-2,058
<b>Balance sheet</b>					
<b>Assets</b>					
Intangible assets			60,867	61,033	60,433
Property, plant and equipment			11,242	13,091	12,023
Non-current assets			74,923	77,519	75,211
Cash and cash equivalents			21,438	23,141	20,084
Current assets			64,489	60,385	62,451
Total assets			139,412	137,904	137,662
<b>Equity and liabilities</b>					
Equity			79,305	77,719	78,015
Non-current liabilities			2,598	19,412	18,155
Current liabilities			57,509	40,773	41,492
Total liabilities			60,107	60,185	59,647
Total equity and liabilities			139,412	137,904	137,662
<b>Cash flow statement</b>					
Depreciation, amortization and impairment			3,464	2,764	6,197
Cash flows from operating activities			4,655	-965	-2,434
Cash flows from investing activities			-2,460	-3,240	-4,831
Cash flows from financing activities			-1,349	-1,872	-2,859
Cash and cash equivalents at the end of period			21,438	23,141	20,084
<b>Key figures and ratios</b>					
Number of shares, average			36,874,082	36,874,082	36,874,082
Basic EPS (DKK)	0.00	-0.03	0.00	-0.01	-0.08
Diluted EPS (DKK)	0.00	-0.03	0.00	-0.01	-0.08
Gross margin	65.3%	65.8%	65.9%	66.9%	64.4%
Assets/Equity (gearing)			1.76	1.77	1.76
Average number of employees			91	85	87
Market price per share (DKK)			14.4	8.2	7.0
Market capitalisation (DKK million)			531	302.4	258.1
Price / net asset value			6.70	3.89	3.31
Net interest bearing debt / Equity			0.08	0.11	0.13
Net interest bearing debt / EBITDA			1.16	5.17	3.39
Interest coverage			3.25	1.57	1.44

Basic and diluted EPS have been calculated in accordance with IAS 33 "Earnings per share". Other ratios have been calculated in accordance with "Recommendations & Financial Ratios 2015" issued by the Danish Society of Financial Analysts, dated April 2015. (\*) EBITDA (defined as Earnings Before Special Items, Interest, Tax, Depreciation and Amortization) includes non-cash costs of share-based payment of tDKK 754 in the first six months of 2015.

## MANAGEMENT REPORT

Reported figures are for the full reporting period unless otherwise stated. Figures for the comparable reporting period in the previous year are stated in parenthesis. In the first six months of 2015 the average USD/DKK exchange rate applied to translate revenue and expenses was DKK 6.72 (DKK 5.44).

### Revenue

In the first six months of 2015 total revenue increased 22% to DKK 77 million (DKK 63.2 million).

Research services and product sales (excluding OEM) drive growth. Sales increased 24% to DKK 61.7 million (DKK 49.8 million) excluding OEM sales of DKK 6.4 million (DKK 4.9 million) in the first six months of 2015.

In Europe services and product sales (excluding OEM) increased 14% to DKK 28.0 million (DKK 24.5 million), and in North America sales increased 40% to DKK 25.2 million (DKK 18.0 million) benefitting from an improved pricing situation following recent increase in the USD/DKK exchange rate. Rest of World sales increased 17% to DKK 8.6 million (DKK 7.3 million).

Services sales initially drive growth as the company targets new markets for RNA sequencing and RNA functional analysis. In the first six months of 2015 services sales increased 65% to DKK 12.5 million (DKK 7.6 million) and product sales (excluding OEM) increased 17% to DKK 49.2 million (DKK 42.2 million).

License income accounted for DKK 4.3 million (DKK 3.7 million) and contract research income, reflective of third party funding of Exiqon's development of novel diagnostics, totaled DKK 3.2 million (DKK 3.6 million).

### Gross profit and margins

In the first six months of 2015 gross profit increased 20% to DKK 50.8 million (DKK 42.3 million) as a result of higher sales volumes. In the same period gross margins on product sales and services excluding other income decreased marginally to 62.2% (62.5%). Short-term margins are affected negatively by increased services sales, relative to product sales, however, improved economies of scale and automated solutions will allow for continued improvement of margins over time as the company continues to execute its growth strategy. In the second quarter of 2015 gross profit increased 23% to DKK 24.8 million (DKK 20.2 million) and gross margins on product sales and services excluding other income improved to 62.3% (61.4%).

### Operating costs

In the first six months of 2015 operating costs excluding production costs increased 13% to DKK 49.0 million (DKK 43.3 million) in line with the company's strategy to maximize investment in R&D and S&M without compromising EBITDA profitability. In the second quarter of 2015 operating costs excluding production costs increased 11% to DKK 24.0 million (DKK 21.7 million).

### EBITDA and EBIT

EBITDA improved to DKK 5.2 million (DKK 1.7 million) whereas EBIT was affected by higher depreciations following increased investments and improved to DKK 1.8 million (DKK -1.1 million). In the second quarter of 2015 EBITDA improved to DKK 2.6 million (DKK 0.1 million) and EBIT to DKK 0.8 million (DKK -1.5 million).

### Tax

Net results for the first and second quarter of 2015 have been positive and Exiqon A/S's tax assets may consequently be capitalized in part before yearend.

### Summarized financial numbers compared to full year outlook

In the table below, the company's realized performance for the first six months of 2015 has been summarized and compared to the outlook for the full year; including an adjustment of the realized numbers to the exchange rate used as basis for the full year outlook (USD/DKK 6.50):

(DKK million)	Realized 2015		
	Realized 2015 (USD/DKK 6.72)	adjusted to USD/DKK 6.50	Outlook 2015 (USD/DKK 6.50)
Revenue	77,0	75,8	155-160
EBITDA	5,2	4,7	~10

### Cash flows

Positive cash flows from operating activities of DKK 4.7 million (DKK -1.0 million) reflective of cash flows from primary activities of DKK 6.9 million (DKK -1.7 million) and net interest and value gains amounted to DKK -2.2 million (DKK 0.8 million).

## Equity and capital resources

Equity increased to DKK 79.3 million (DKK 77.7 million). On 30 June 2015 cash and cash equivalents totalled DKK 21.4 (DKK 23.1 million). Trade receivables increased to DKK 21.2 million (DKK 16.5 million) as a result of higher sales whereas trade payables of DKK 10.3 million (DKK 10.7 million) was largely unchanged as a result of continued cash management efforts. DKK 10 million in credit is subject to repayment by 10 January 2016 and proceeds of DKK 15 million from the company's corporate bond is subject to repayment by 1 March 2016. Management expects that the company's future capital needs are covered by existing arrangements. Any requirement for additional capital in the future, we will seek to cover by continuing the existing arrangements beyond their current terms, replacing them with new arrangements on similar terms, or increasing the current share capital under existing authorizations to the Supervisory Board.

## FINANCIAL OUTLOOK 2015

Exiqon now expects revenues between DKK 155-160 million (previously DKK 150-160 million) and EBITDA around DKK 10 million (previously DKK 5-10 million) in 2015.

The outlook for 2015 is still based on an average USD/DKK exchange rate of DKK 6.50.

In addition to exchange rates, the outlook depends primarily on organic growth in Exiqon's services and product sales, excluding OEM sales to licensees. Exiqon continues to pursue license and partnering opportunities during 2015. No significant one-time costs are included in the outlook for 2015, nor are any expected. Any costs related to new warrant grants are not included in the guidance for 2015.

## STATEMENT BY THE EXECUTIVE BOARD AND SUPERVISORY BOARD ON THE INTERIM REPORT

The Supervisory Board and the Executive Board have today considered and approved the interim report of Exiqon A/S for the period 1 January – 30 June 2015.

The interim report has been prepared in accordance with IAS 34 and additional Danish disclosure requirements for the presentation of financial statements by listed companies. The interim report is unaudited.

We consider the accounting policies to be appropriate, the accounting estimates made to be reasonable and the overall presentation of the interim report to be adequate, so that the interim report, in our opinion, gives a true and fair view of the assets, liabilities, financial position and results of operations and cash flows of the group for the period 1 January – 30 June 2015. We consider the Management's report to give a true and fair description of the development in the Group's activities and economic situation, the results of operations and the Group's financial position as a whole and a description of the significant risks and uncertainty factors, which the Group faces.

Vedbaek, 25 August 2015

### Executive Board

Lars Kongsbak, CEO

Hans Henrik Chrois Christensen, CFO

### Supervisory Board

Erik Walldén, chairman

Thorleif Krarup, deputy chairman

Michael Nobel

Per Wold-Olsen

Rodney Turner

### Additional information

Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

### Forward-looking statements

*Certain parts of this release contain forward-looking information with respect to the plans, projections and future performance of the company, each of which involves significant uncertainties. The company's actual results may differ materially from the information set forth in these statements. Timelines relating to collaborative diagnostic programs should be considered approximate.*

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)**

(DKK'000)	Note	1 Apr. – 30 Jun. 2015	1 Apr. – 30 Jun. 2014	1 Jan. – 30 Jun. 2015	1 Jan. – 30 Jun. 2014	1 Jan. – 31 Dec. 2014
Revenue	2,3	38,016	30,722	77,038	63,193	132,392
Production costs		-13,176	-10,505	-26,270	-20,930	-47,193
<b>Gross profit</b>		<b>24,840</b>	<b>20,217</b>	<b>50,768</b>	<b>42,263</b>	<b>85,199</b>
Research and development costs		-7,733	-6,469	-16,052	-13,138	-26,283
Sales and marketing costs		-11,951	-10,510	-24,131	-20,901	-43,087
Administrative costs		-4,334	-4,765	-8,814	-9,280	-18,911
<b>Operating profit/(loss) (EBIT)</b>		<b>822</b>	<b>-1,527</b>	<b>1,771</b>	<b>-1,056</b>	<b>-3,082</b>
Financial income		1,454	292	3,582	652	2,210
Financial expenses		-2,398	-929	-5,723	-1,836	-5,111
<b>Profit/(loss) before tax</b>		<b>-122</b>	<b>-2,164</b>	<b>-370</b>	<b>-2,240</b>	<b>-5,983</b>
Tax on profit/(loss) for the period		137	921	414	1,790	3,203
<b>Profit/(loss) for the period</b>		<b>15</b>	<b>-1,243</b>	<b>44</b>	<b>-450</b>	<b>-2,780</b>
<b>Other comprehensive income</b>						
Items that may be reclassified subsequently to profit or loss:						
Exchange adjustments relating to foreign subsidiaries		-684	90	492	46	722
<b>Total comprehensive income for the period</b>		<b>-669</b>	<b>-1,153</b>	<b>536</b>	<b>-404</b>	<b>-2,058</b>
<b>Earnings per share</b>						
Earnings per share		0.00	-0.03	0.00	-0.01	-0.08
Diluted earnings per share		0.00	-0.03	0.00	-0.01	-0.08

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)

(DKK'000)	Note	30 Jun. 2015	30 Jun. 2014	31 Dec. 2014
Goodwill		49,368	49,368	49,368
Acquired patent rights		4,462	5,412	4,887
Acquired software licenses		6,183	6,023	5,932
Intangible assets under construction		854	230	246
<b>Intangible assets</b>		<b>60,867</b>	<b>61,033</b>	<b>60,433</b>
Leasehold improvements		569	668	663
Production and laboratory equipment		8,306	10,370	9,474
Fixtures and fittings, tools and equipment		2,367	1,933	1,777
Tangible assets under construction		0	120	109
<b>Property, plant and equipment</b>		<b>11,242</b>	<b>13,091</b>	<b>12,023</b>
Deferred tax assets		1,455	1,709	1,430
Deposits		1,359	1,686	1,325
<b>Financial assets</b>		<b>2,814</b>	<b>3,395</b>	<b>2,755</b>
<b>Non-current assets</b>		<b>74,923</b>	<b>77,519</b>	<b>75,211</b>
<b>Inventories</b>		<b>13,561</b>	<b>14,195</b>	<b>13,963</b>
Trade receivables		21,183	16,487	22,147
Other receivables		1,912	1,682	1,200
Refund from Tax Authorities		4,134	3,250	3,690
Prepayments		2,261	1,630	1,367
<b>Receivables</b>		<b>29,490</b>	<b>23,049</b>	<b>28,404</b>
<b>Cash and cash equivalents</b>		<b>21,438</b>	<b>23,141</b>	<b>20,084</b>
<b>Current assets</b>		<b>64,489</b>	<b>60,385</b>	<b>62,451</b>
<b>Total assets</b>		<b>139,412</b>	<b>137,904</b>	<b>137,662</b>
Share capital		36,874	36,874	36,874
Reserves		42,431	40,845	41,141
<b>Equity</b>		<b>79,305</b>	<b>77,719</b>	<b>78,015</b>
Corporate Bonds		0	15,000	15,000
Financial lease liabilities		2,598	4,412	3,155
<b>Non-current liabilities</b>		<b>2,598</b>	<b>19,412</b>	<b>18,155</b>
Corporate Bonds		15,000	0	0
Financial lease liabilities		2,414	2,525	2,439
Trade payables		10,284	10,706	10,505
Short term bank loan		9,911	10,036	10,018
Other payables		12,225	8,452	10,394
Deferred revenue		7,675	9,054	8,136
<b>Current liabilities</b>		<b>57,509</b>	<b>40,773</b>	<b>41,492</b>
<b>Total liabilities</b>		<b>60,107</b>	<b>60,185</b>	<b>59,647</b>
<b>Total equity and liabilities</b>		<b>139,412</b>	<b>137,904</b>	<b>137,662</b>

## CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

(DKK'000)	1 Jan. – 30 Jun. 2015	1 Jan. – 30 Jun. 2014	1 Jan. – 31 Dec. 2014
Operating profit/(loss) (EBIT)	1,771	-1,056	-3,082
Depreciation and amortization	3,464	2,764	6,197
Non-cash adjustments (warrants)	754	1,904	3,854
Change in working capital	873	-5,357	-9,403
Profit on sale of assets	0	0	-146
<b>Cash flows from primary activities</b>	<b>6,862</b>	<b>-1,745</b>	<b>-2,580</b>
Net interest and value gains	-2,598	-1,176	-3,497
Current tax	391	1,956	3,643
<b>Cash flows from operating activities</b>	<b>4,655</b>	<b>-965</b>	<b>-2,434</b>
Acquisition of intangible assets	-2,033	-1,417	-2,382
Acquisition of property, plant and equipment	-427	-1,823	-2,595
Sale of assets	0	0	146
<b>Cash flows from investing activities</b>	<b>-2,460</b>	<b>-3,240</b>	<b>-4,831</b>
Repayment of lease debt	-1,220	-1,872	-3,215
Repayment of deposit and loans	-22	-23	351
Short term bank loan	-107	23	5
<b>Cash flows from financing activities</b>	<b>-1,349</b>	<b>-1,872</b>	<b>-2,859</b>
<b>Change in cash and cash equivalents</b>	<b>846</b>	<b>-6,077</b>	<b>-10,124</b>
Unrealised currency gain/(loss)	508	28	1,018
Cash and cash equivalents at the beginning of the period	20,084	29,190	29,190
<b>Cash and cash equivalents at the end of the period</b>	<b>21,438</b>	<b>23,141</b>	<b>20,084</b>

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

	Number of shares No.	Share capital (DKK'000)	Other reserves				Total (DKK'000)
			Reserve for exchange adjustments (DKK'000)	Share- based payment (DKK'000)	Retained profit (DKK'000)		
<b>Consolidated</b>							
<b>Equity at 1 January 2015</b>	<b>36,874,082</b>	<b>36,874</b>	<b>98</b>	<b>20,195</b>	<b>20,848</b>		<b>78,015</b>
Profit/(loss) for the period					44		44
Exchange adjustments relating to foreign subsidiaries			492				492
<b>Total comprehensive income</b>		<b>0</b>	<b>492</b>	<b>0</b>	<b>44</b>		<b>536</b>
Share-based payment				754			754
<b>Other transactions</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>754</b>	<b>0</b>		<b>754</b>
<b>Equity at 30 June 2015</b>	<b>36,874,082</b>	<b>36,874</b>	<b>590</b>	<b>20,949</b>	<b>20,892</b>		<b>79,305</b>
<b>Equity at 1 January 2014</b>	<b>36,874,082</b>	<b>36,874</b>	<b>-624</b>	<b>16,341</b>	<b>23,628</b>		<b>76,219</b>
Profit/(loss) for the period					-450		-450
Exchange adjustments relating to foreign subsidiaries			46				46
<b>Total comprehensive income</b>		<b>0</b>	<b>46</b>	<b>0</b>	<b>-450</b>		<b>-404</b>
Share-based payment				1,904			1,904
<b>Other transactions</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1,904</b>	<b>0</b>		<b>1,904</b>
<b>Equity at 30 June 2014</b>	<b>36,874,082</b>	<b>36,874</b>	<b>-578</b>	<b>18,245</b>	<b>23,178</b>		<b>77,719</b>



## NOTES TO THE INTERIM FINANCIAL STATEMENTS

### Note 1 Accounting policies

The interim report of the Exiqon Group for the period 1 January – 30 June 2015 is presented in accordance with IAS 34 and additional Danish disclosure requirements for the presentation of financial statements by listed companies. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's Annual Report for 2014.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in preparation of the Group's annual consolidated financial statements for the year that ended 31 December 2014. Management has not made new significant accounting estimates and assumptions on topics besides those listed in the Annual Report for 2014.

### Note 2 Revenue

(DKK'000)	1 Apr. – 30 Jun. 2015	1 Apr. – 30 Jun. 2014	1 Jan. – 30 Jun. 2015	1 Jan. – 30 Jun. 2014	1 Jan. – 31 Dec. 2014
Product sales	29,019	23,469	57,078	48,310	96,269
Services	5,929	3,731	12,486	7,577	20,507
License income	1,457	1,354	4,316	3,669	8,912
Contract research and grants income	1,611	2,168	3,158	3,637	6,704
	<b>38,016</b>	<b>30,722</b>	<b>77,038</b>	<b>63,193</b>	<b>132,392</b>

In the second quarter, product sales includes OEM of DKK 3.5 million (DKK 1.7 million) and shipping & handling of DKK 0.8 million (DKK 0.6 million).

### Note 3 Segment information

Exiqon's Management has organized the reporting in two reportable operating segments: Exiqon Life Sciences and Exiqon Diagnostics. The Group divides its revenue into three geographies: North America, Europe and Rest of World. The split is based on the registered offices of the customers.

Management monitors the operating results of its business segments separately to decide the resource allocation and performance assessments. Segment performance is monitored on operating results (EBITDA/EBIT) as presented in the table below. Financial items and taxes are managed on a corporate level and not allocated to the operating segments.

(DKK'000)	Life Sciences	Diagnostics	Group eliminations	Other <sup>1)</sup>	Consolidated
Revenue:					
External customers	75,525	1,513	0	0	77,038
Internal customers	18,084	0	-18,084	0	0
Total revenue	93,609	1,513	-18,084	0	77,038
EBITDA	13,526	-8,291	0	0	5,235
Operating profit/(loss) (EBIT)	10,571	-8,800	0	0	1,771
Net non-operating cost	0	0	0	-2,141	-2,141
Profit (loss) before tax	10,571	-8,800	0	-2,141	-370
Assets	59,897	53,943	0	25,572	139,412

1) The item 'Other' includes net non-operating items.

### Geography

Revenue of the Exiqon Group is distributed on geographical segments as follows:

(DKK'000)	1 Apr. – 30 Jun. 2015	1 Apr. – 30 Jun. 2014	1 Jan. – 30 Jun. 2015	1 Jan. – 30 Jun. 2014	1 Jan. – 31 Dec. 2014
North America	15,410	10,152	29,660	21,631	45,576
Europe	18,478	17,990	38,172	33,821	72,000
Rest of World	4,128	2,580	9,206	7,741	14,816
	<b>38,016</b>	<b>30,722</b>	<b>77,038</b>	<b>63,193</b>	<b>132,392</b>

--oo0oo--